Micell has a strong intellectual property portfolio consisting of 100 issued U.S. and International patents covering a variety of applications of supercritical fluids. Specifically, Micell's intellectual property portfolio surrounding biomedical applications includes patents and patent applications involving supercritical fluids either owned by Micell, or exclusively licensed from distinguished institutions such as Battelle Memorial Institute. Micell owns or controls intellectual property covering the use of supercritical fluids and related process methods in the following biomedical applications:
- Controlling the morphology, distribution and drug-delivery characteristics of drugs in sustained-release coatings and drug delivery materials
- Coating of complex medical devices with drug/polymer formulations
- 'Dry', low-temperature drug/polymer coating processes that maintain the structure and morphology of therapeutic agents
With its first core patent expiration years away in 2022, Micell is continuing to innovate, and complements its patent portfolio with an important body of proprietary supercritical fluid expertise.
